AR076891A1 - Metodo para la preparacion de clorhidrato de nalmefeno - Google Patents

Metodo para la preparacion de clorhidrato de nalmefeno

Info

Publication number
AR076891A1
AR076891A1 ARP100101818A ARP100101818A AR076891A1 AR 076891 A1 AR076891 A1 AR 076891A1 AR P100101818 A ARP100101818 A AR P100101818A AR P100101818 A ARP100101818 A AR P100101818A AR 076891 A1 AR076891 A1 AR 076891A1
Authority
AR
Argentina
Prior art keywords
naltrexone
organic phase
optionally
nalmefene
solid
Prior art date
Application number
ARP100101818A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076891(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR076891A1 publication Critical patent/AR076891A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Método para la produccion de clorhidrato de nalmefeno a partir de naltrexona. Reivindicacion 1: Un método para preparar nalmefeno a partir de naltrexona en una reaccion de Wittig en la cual se utiliza 2-metiltetrahidrofurano (MTHF) tanto en la formacion de un iluro de fosforo como en la reaccion subsiguiente entre dicho iluro y naltrexona. Reivindicacion 2: El método de acuerdo con la reivindicacion 1, que comprende los siguientes pasos: a) preparacion de un iluro de fosforo mezclando una sal de metiltrifenilfosfonio con MTHF y una base adecuada y b) adicion de una mezcla que comprende naltrexona y MTHF a la mezcla obtenida en el paso a). Reivindicacion 12: Un método para aislar el nalmefeno obtenido en el paso b) de acuerdo con cualquiera de las reivindicaciones anteriores, método que comprende los siguientes pasos; c) (i) mezclar una solucion acuosa que comprende cloruro de amonio (NH4CI) con la mezcla obtenida en el paso b) o (ii) mezclar un ácido o una solucion con contenido de ácido con la mezcla obtenida en el paso b), (iii) mezclar una cetona con la mezcla obtenida en el paso b) o (iv) realizar una combinacion de los mencionados pasos (i), (ii) y (iii), y a continuacion (v) opcionalmente, diluir con agua, (d) separar la fase orgánica obtenida en el paso c), e) opcionalmente, lavar la fase orgánica obtenida en c) con agua y separar la fase orgánica, f) concentrar la fase orgánica obtenida en el paso d) o e) al vacío para eliminar los volátiles, g) diluir el residuo obtenido en el paso f) con uno o más solventes orgánicos apropiados, h) agregar cloruro de hidrogeno (HCI) a la mezcla obtenida en el paso g), i) aislar el solido así obtenido, j) opcionalmente, resuspender el solido obtenido en el paso i) en uno o más solventes apropiados y aislar el solido y k) opcionalmente, secar el solido final.
ARP100101818A 2009-05-25 2010-05-26 Metodo para la preparacion de clorhidrato de nalmefeno AR076891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200900650 2009-05-25

Publications (1)

Publication Number Publication Date
AR076891A1 true AR076891A1 (es) 2011-07-13

Family

ID=43222172

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101818A AR076891A1 (es) 2009-05-25 2010-05-26 Metodo para la preparacion de clorhidrato de nalmefeno

Country Status (35)

Country Link
US (1) US8598352B2 (es)
EP (1) EP2435439B8 (es)
JP (1) JP5794980B2 (es)
KR (1) KR101716522B1 (es)
CN (1) CN102459276B (es)
AR (1) AR076891A1 (es)
AU (1) AU2010252392B2 (es)
BR (1) BRPI1010975B1 (es)
CA (1) CA2763093C (es)
CL (1) CL2011002974A1 (es)
CO (1) CO6470832A2 (es)
CR (1) CR20110612A (es)
DK (1) DK2435439T3 (es)
DO (1) DOP2011000362A (es)
EA (1) EA019331B1 (es)
ES (1) ES2564006T3 (es)
GE (1) GEP20146190B (es)
HR (1) HRP20160110T1 (es)
HU (1) HUE026892T2 (es)
IL (1) IL216422A (es)
MA (1) MA33368B1 (es)
ME (1) ME02622B (es)
MX (1) MX2011012502A (es)
MY (1) MY158251A (es)
NZ (1) NZ596988A (es)
PL (1) PL2435439T3 (es)
RS (1) RS54599B1 (es)
SG (1) SG176205A1 (es)
SI (1) SI2435439T1 (es)
SM (1) SMT201600061B (es)
TN (1) TN2011000590A1 (es)
TW (1) TWI469985B (es)
UA (1) UA106752C2 (es)
WO (1) WO2010136039A1 (es)
ZA (1) ZA201108659B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2995614B8 (en) 2010-06-11 2018-03-28 Rhodes Technologies Inc. Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
SI2635586T1 (sl) 2010-11-05 2017-07-31 H. Lundbeck A/S Metoda za izdelavo naltreksona
CN103012416B (zh) * 2011-09-28 2015-07-01 辽宁海思科制药有限公司 一种盐酸纳美芬的制备方法
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CN102584840A (zh) * 2011-12-28 2012-07-18 南京优科生物医药有限公司 一种制备纳美芬化合物的方法
WO2013164383A1 (en) 2012-05-03 2013-11-07 H. Lundbeck A/S Method for the manufacturing of naltrexone
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
CN103204859B (zh) * 2013-04-25 2015-12-02 四川海思科制药有限公司 一种盐酸纳美芬化合物及其制备方法
AR096851A1 (es) * 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
EP3082815B1 (en) 2013-12-20 2018-10-03 H. Lundbeck A/S Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
RU2016145411A (ru) 2014-04-22 2018-05-23 Оцука Фармасьютикал Ко., Лтд. Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости
CN104513251A (zh) * 2014-11-28 2015-04-15 安徽悦康凯悦制药有限公司 一种盐酸纳美芬的制备方法
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
RU2712232C1 (ru) * 2018-10-05 2020-01-27 Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства Улучшенный способ получения налмефена из налтрексона
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
JP2023548356A (ja) 2020-11-02 2023-11-16 ローズ テクノロジーズ ノルオキシモルホンを精製するための方法
US20240109907A1 (en) 2021-01-28 2024-04-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) * 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US7687646B2 (en) 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene

Also Published As

Publication number Publication date
SG176205A1 (en) 2011-12-29
ME02622B (me) 2017-06-20
WO2010136039A1 (en) 2010-12-02
US20120123123A1 (en) 2012-05-17
MX2011012502A (es) 2011-12-12
ZA201108659B (en) 2013-02-27
PL2435439T3 (pl) 2016-05-31
SMT201600061B (it) 2016-07-01
CN102459276B (zh) 2016-09-21
AU2010252392A1 (en) 2012-01-12
EP2435439A1 (en) 2012-04-04
NZ596988A (en) 2013-03-28
CL2011002974A1 (es) 2012-04-13
RS54599B1 (en) 2016-08-31
JP2012527489A (ja) 2012-11-08
MA33368B1 (fr) 2012-06-01
BRPI1010975A2 (pt) 2015-10-20
DOP2011000362A (es) 2012-07-15
CN102459276A (zh) 2012-05-16
US8598352B2 (en) 2013-12-03
CR20110612A (es) 2012-02-22
EP2435439B8 (en) 2016-05-18
HRP20160110T1 (hr) 2016-03-11
BRPI1010975B1 (pt) 2021-08-24
EA019331B1 (ru) 2014-02-28
IL216422A (en) 2015-06-30
IL216422A0 (en) 2012-02-29
HUE026892T2 (en) 2016-07-28
GEP20146190B (en) 2014-11-10
KR20120023704A (ko) 2012-03-13
SI2435439T1 (sl) 2016-06-30
ES2564006T3 (es) 2016-03-17
TWI469985B (zh) 2015-01-21
EP2435439B1 (en) 2016-01-06
UA106752C2 (uk) 2014-10-10
KR101716522B1 (ko) 2017-03-14
CA2763093C (en) 2017-03-07
JP5794980B2 (ja) 2015-10-14
TW201043634A (en) 2010-12-16
CA2763093A1 (en) 2010-12-02
AU2010252392B2 (en) 2014-10-23
EA201171461A1 (ru) 2012-05-30
TN2011000590A1 (en) 2013-05-24
MY158251A (en) 2016-09-30
CO6470832A2 (es) 2012-06-29
DK2435439T3 (en) 2016-02-29

Similar Documents

Publication Publication Date Title
AR076891A1 (es) Metodo para la preparacion de clorhidrato de nalmefeno
EA201491146A1 (ru) Способ извлечения карбоновой кислоты из водного раствора
NZ734535A (en) Process of producing cycloalkylcarboxamido-indole compounds
CO6541539A2 (es) Procesos para preparar las formas cristalinas a y b de ilaprazol y proceso para convertir las formas cristalinas
MY167395A (en) Method for producing glufosinate p free acid
EA201200652A1 (ru) Способ получения кальцобутрола
WO2012075091A3 (en) Synthetic acid and associated methods
WO2012018418A3 (en) Method and device for carboxylic acid production
PH12014501457B1 (en) Method for producing cobalt sulfate
IN2013CN00459A (es)
NZ751256A (en) Method for producing the crystalline form of modification a of calcobutrol
BR102014005754B8 (pt) composto,e, método para a preparação de um composto
DOP2011000007A (es) Produccion de concetrados de sulfato de cinc de una solucion diluida de sulfato de cinc.
MX2018005046A (es) Metodo para producir flutemetamol.
AR090916A1 (es) Metodo para la fabricacion de naltrexona
BR112015003520A2 (pt) método para a produção de (r)-1,1,3-trimetil-4-aminoindano
NZ620043A (en) Methods of isolating 4-chloro-2-fluoro-3-substituted-phenylboronic acids
AR089080A1 (es) Proceso de recuperacion de clorhidrato de nalmefeno
SG11201401103YA (en) Process for the preparation of formic acid by reaction of carbon dioxide with hydrogen
MX339065B (es) Proceso para elaborar una composicion detergente base.
EA200801963A1 (ru) СПОСОБ ПОЛУЧЕНИЯ ПОЛИМОРФНОЙ ФОРМЫ I ГИДРОСУЛЬФАТА (S)-(+)-МЕТИЛ-α-(2-ХЛОРФЕНИЛ)-6,7-ДИГИДРОТИЕНО-[3,2-C] ПИРИДИН-5(4H)-АЦЕТАТА
WO2009156279A3 (en) Process for the preparation of clopidogrel hydrogen sulfate crystalline form i
WO2011083955A3 (en) Method for manufacturing crystalline form (i) of clopidogrel hydrogen sulphate
WO2013071412A8 (en) Methods for the synthesis of 13c labeled plasmalogen
MX364766B (es) Proceso para la preparacion de un derivado sulfatado de 3,5-diiodo-o-[3-iodofenil]-l-tirosina.

Legal Events

Date Code Title Description
FB Suspension of granting procedure